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Systemic Sclerosis (SSc) is an autoimmune inflammatory disorder of unknown etiology 
characterized by severe and often progressive cutaneous and visceral fibrosis, pronounced 
alterations in the microvasculature and frequent cellular and humoral immunity abnormalities, 
culminating in a severe and progressive fibrotic process.  Numerous biomarkers reflecting the 
three main pathogenetic mechanisms in SSc have been described, however, aside from several 
disease-specific autoantibodies other biomarkers have not been thoroughly validated and they 
would need further study. Thus, there is an unmet need for validated biomarkers for diagnosis, 
disease classification, and evaluation of organ involvement and therapeutic response in SSc. 
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Introduction  
 Systemic Sclerosis (SSc) is an autoimmune inflammatory disorder of unknown etiology 
characterized by severe and often progressive cutaneous and visceral fibrosis, pronounced 
alterations in the microvasculature and frequent cellular and humoral immunity abnormalities [1-
4].  Clinically, SSc is heterogeneous, ranging from skin sclerosis confined to the fingers, face 
and/or distal parts of the extremities (sclerodactyly or acrosclerosis) with limited internal organ 
involvement, to diffuse skin involvement and severe fibrosis of multiple internal organs, and 
occasionally a fulminant course with rapid development of vital organ failure and a lethal 
outcome (fulminant SSc) [5].  The most apparent and almost universal clinical features of SSc 
are related to the progressive fibrosis of the skin, the microvasculature, and numerous internal 
organs.  Morbidity and mortality in SSc are high and are related to the extent of the fibrotic and 
microvascular alterations.  The extent and rate of progression of tissue fibrosis is of paramount 
importance in determining the clinical features and the prognosis of SSc. Indeed, fibrosis of the 
skin correlates with both survival and functional limitations [5-7].     
The etiology of SSc is not known, however, it is currently accepted that the disease 
results from complex interactions between one or more environmental factors and a genetic 
predisposition in the host [1-4]. These genetics-environmental interactions eventually result in 
the development of generalized and often progressive skin and tissue fibrosis accompanied by a 
severe fibroproliferative/occlusive vasculopathy and by prominent abnormalities in cellular and 
humoral immunity with the occurrence of chronic inflammatory cell infiltration, derangement of 
cytokine and growth factor functional balance and development of numerous autoantibodies as 
illustrated in Figure 1 [3,4,8].  At present, it is not clear which of these components of SSc 
pathogenesis is of primary importance or how they interrelate to cause the progressive fibrotic 
process.  However, numerous recent studies have suggested that there is a sequence of 
pathogenetic events initiated by unknown etiologic factors that trigger microvascular injury with 
prominent structural and functional endothelial cell abnormalities which result in progressive 
fibroproliferative vasculopathy and vessel rarefaction [9-11]. The endothelial dysfunction also 
leads to the attraction of specific cellular elements from the bloodstream and bone marrow and 
their transmigration into the surrounding tissue, leading to the establishment of a chronic 
inflammatory process with participation of macrophages and T- and B- lymphocytes and the 
secretion and release of a variety of cytokines and growth factors from these cells.  This 
sequence of events, diagrammatically illustrated in Figure 2, culminates in the development of a 
severe and progressive fibrotic process and in the production of disease-specific autoantibodies.   
The remarkable progress in the understanding of numerous basic mechanisms involved in the 
complex pathogenesis of SSc has opened new avenues for the development of novel and 
effective therapeutic approaches.  At the same time, it has become apparent that there is an 
unmet need for validated biomarkers that can be used for diagnosis, disease classification, 
identification of organ involvement, and evaluation of therapeutic response in SSc. 
 
Biomarkers in Systemic Sclerosis  
The NIH Biomarkers Definitions Working Group was convened by the NIH Director’s 
initiative on Biomarkers and Surrogate Endpoints.  The expert working group provided 
definitions and identified the characteristics and requirements of biological measurements to be 
employed for the development and assessment of human therapeutics.  A “Biological Marker” or 
“Biomarker” was defined as a characteristic that is OBJECTIVELY measured and evaluated as an 
indicator of normal biologic processes, pathogenic processes or pharmacologic responses to a 
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therapeutic intervention.  Other important characteristics of a biomarker include the following: it 
should reflect the underlying biologic process being evaluated; should allow the prediction of 
clinical course or prognosis of a disease process; should be sensitive to therapeutic effects; 
should be easily obtainable, preferably by non-invasive means; and should eventually be 
validated in clinical studies. 
Although there has been extensive interest in the development of outcome measures for SSc 
[12-16], biomarkers that allow early diagnosis and assessment of disease activity or that carry a 
predictive prognostic value are not available for SSc. The clinical semi-quantitative assessment 
of skin thickness (modified Rodnan skin score or mRSS) is currently the gold standard and the 
only outcome measure used in clinical trials of SSc disease modifying agents.  The original 
description of the method showed that the score correlated with skin biopsy sample weight and, 
thus, it was assumed to be a reflection of the fibrotic process causing skin induration and 
thickening. Although non-invasive and cost effective, the mRSS entails several shortcomings, 
ranging from the subjectivity of skin palpation assessments to the difficulty of scoring borderline 
changes in skin involvement.  Furthermore, it is not possible to differentiate fibrotic skin 
thickening from that resulting from tissue edema, inflammation, vascular bed engorgement or 
skin tethering.  It is, therefore, generally accepted that the development of objective and reliable 
markers reflecting the severity of tissue fibrosis would be of invaluable help in determining the 
efficacy of a given treatment in clinical trials, both by allowing a reduction in the number of 
patients needed for the studies to achieve statistical power and by offering an objective and 
quantitative method independent of the subjective assessment of the investigators involved in the 
study.  
In contrast to the remarkable progress with biomarkers for cancer and cardiovascular 
disease [17-20], there are very few validated biomarkers for the assessment of SSc disease 
activity and for clinical subset disease classification, and their utility has not been extensively 
tested or validated in clinical trials [21].  Most importantly, there is an important need to 
develop, test, and validate accurate and objective measures of tissue fibrosis and vasculopathy in 
SSc and markers that may reflect a therapeutic response of the disease process for use in clinical 
trials. 
 Biomarkers for SSc can be grouped based on their ability to assist in SSc diagnosis 
(“diagnostic biomarkers”), to determine distinct clinical subsets which may have specific 
patterns of organ involvement or evolution (“clinical subset biomarkers”), to predict specific 
organ involvement or specific clinical manifestation such as for example tissue fibrosis (“fibrosis 
biomarker”) or vascular alterations (“vascular biomarker”), and to assess disease activity which 
may allow prediction of the clinical course or mortality (“prognostic biomarker”) or 
determination of the effectiveness of a therapeutic intervention (“therapeutic response 
biomarker”).  This latter group of biomarkers are also often utilized as endpoints in clinical trials 
of potential treatments or interventions.   
 
Autoantibodies as Systemic Sclerosis Diagnostic Biomarkers 
 At present there are no specific diagnostic tests for SSc and the disorder is diagnosed 
primarily based on the collective appearance of a cluster of clinical symptoms such as, for 
example, Raynaud’s phenomenon, telangiectasias, esophageal dysfunction with gastro-
esophageal reflux, characteristic pigmentary changes, presence of digital ulcers, or calcinotic 
lesions accompanying clinically detectable skin induration.  Indeed, the diagnostic criteria 
commonly employed for classification of SSc is entirely based on clinical manifestations and 
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does not include any measurable serologic or laboratory parameters.  However, it is well 
recognized that the presence of specific autoantibodies is one of the most common 
manifestations of SSc and greater than 90% of SSc patients harbor antinuclear antibodies in their 
serum [22-25].  Numerous autoantibodies have been described in SSc patients (Table 1).  Some 
of these are highly specific for SSc including anti-Scl-70 and anti-centromere antibodies and 
have been, therefore, used as Diagnostic Biomarkers to support or confirm the clinical diagnosis 
of SSc.  Anti-Scl-70 antibodies are directed against DNA topoisomerase I and are almost 
exclusively present in sera from patients with the diffuse form of SSc [26,27], and they correlate 
with the development of severe interstitial lung disease.  Anti-centromere antibodies recognize 
several protein components of the tri-laminar kinetochore [28].  These antibodies are usually 
present in patients with the limited form of SSc and are found in 45-50% of these patients.  In 
contrast to anti-Scl-70 antibodies, anti-centromere antibodies are only found in about 10% of 
patients with diffuse SSc.  These two autoantibodies are mutually exclusive, co-existing in the 
same patient only in rare instances.   
 There are numerous other autoantibodies less commonly present in SSc patients, 
including anti-RNA polymerases I and III antibodies in patients with rapidly progressive diffuse 
disease and high frequency of SSc renal crisis, anti-fibrillarin antibodies commonly found in 
diffuse SSc, and anti-PM-Scl antibodies that are often present in patients with a 
polymyositis/SSc overlap syndrome [29-31].     
 
Biomarkers for Clinical Disease Subset Classification 
 It has long been recognized that there are at least two distinct clinical subsets of SSc 
differing in their clinical presentation and evolution, but most importantly, with clearly different 
outcomes regarding frequency and severity of organ involvement as well as overall mortality 
[5,32-34].  The extent of cutaneous sclerotic involvement has been found to accurately 
distinguish the two clinical subsets in the majority of cases.  The first subset is characterized by 
diffuse cutaneous involvement frequently including the thighs, abdomen and chest, associated 
with a progressive course, frequent and severe visceral organ involvement occurring in the early 
stages of disease evolution including development of SSc renal crisis and pulmonary fibrosis and 
high SSc-related mortality.  In contrast, in the second subset there is limited cutaneous 
involvement confined to the acral parts of the extremities and the face, and usually displays a 
more prolonged and protracted evolution, lesser severity of visceral organ involvement except 
for the relatively common occurrence of Pulmonary Arterial Hypertension (PAH) at a late stage 
of the disease, and a more benign prognosis with prolonged overall survival.  When fully 
established the two clinical SSc  subsets display clearly distinguishable patterns of cutaneous 
involvement, however, in early stages of presentation their manifestations often overlap.  Thus, 
there is a substantial need for biomarkers that may allow the accurate identification of the 
clinical SSc subset at early stages of disease.  Although currently there are no specific 
biomarkers to separate these two clinical subsets, the pattern of antinuclear autoantibodies 
present in the sera of affected individuals can be considered as biomarkers of the pattern of 
disease subset; anticentromere antibodies are almost exclusively present in the limited SSc 
subset, whereas Scl-70, anti RNA polymerase I and III, and anti-fibrillarin antibodies are almost 
exclusively associated with the diffuse form of SSc [22-31]. 
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Biomarkers of Endothelial Cell Dysfunction   
Vascular dysfunction is considered to be one of the earliest clinical manifestations of SSc 
and it has been suggested to be a crucial initiating event in SSc pathogenesis [9-11,35-38] as 
illustrated in Figure 2.  Endothelial injury leads to pronounced vascular fibroproliferative lesions 
in multiple organs, however, the effects of vascular dysfunction are most dramatic when they 
involve the pulmonary and renal arterioles, causing renal crisis and PAH, respectively, the two 
most prevalent causes of morbidity and mortality in patients with SSc.  
Since the pioneering studies of Kahaleh and LeRoy, focusing attention on the important 
role of endothelial cells in SSc pathogenesis and their original demonstration that specific 
endothelial cell proteins such as the von Willebrand factor (vWf) are abnormally elevated in the 
sera of patients with SSc [36], there has been intense investigation and numerous studies have 
described potentially important biomarkers that may provide information about the functional 
status of endothelial cells and their dysfunction in SSc [39-43].  In the original study of Kahaleh 
[36], vWf was found elevated in the plasma of patients with SSc and patients with Raynaud’s 
phenomenon, in comparison with normal controls.  These studies have been confirmed 
subsequently, and it has been suggested that this biomarker correlates with the severity of SSc 
[39] and with the presence of pulmonary involvement [44] and the extent of radiologically 
demonstrated interstitial lung disease [45].  Of interest was the observation that ADAMTS-13, an 
enzyme that is involved in the cleavage and processing of vWf, was found to be reduced in 
patients with SSc, suggesting that measurements of the activity of this enzyme may represent a 
biomarker of vascular involvement or endothelial cell dysfunction in patients with the disorder 
[46].   
Numerous other molecules involved in different aspects of the pathogenesis of 
endothelial dysfunction in SSc have also been suggested as potential biomarkers for endothelial 
perturbations in the disorder.  Among these are circulating levels of adhesion molecules, 
thrombospondin, thrombomodulin, endothelin-1, the N-terminal pro-peptide of the brain 
natriuretic peptide (NT-pro-BNP), vascular endothelial growth factor (VEGF), endostatin, 
plasminogen activator, and metabolites of the arachidonic acid cascade such as prostacyclin and 
thromboxane or nitrous oxide circulating metabolites.   
Endothelin-1 (ET-1), is a 21-amino acid polypeptide produced by endothelial cells 
capable of potent vasoconstrictive activity and the ability to stimulate proliferation of smooth 
muscle cells.  Numerous studies have conclusively demonstrated that ET-1 and its specific 
cellular receptors play a crucial role in the proliferative vasculopathy of SSc, in particular, in the 
vascular alterations of SSc-associated PAH [47-50].  Thus, there has been intense interest in ET-
1 measurements as a biomarker of SSc vasculopathy.  Serum ET-1 levels have been found to be 
elevated in plasma of SSc patients and to increase following cold exposure and triggering of 
Raynaud’s phenomenon.  Elevated ET-1 levels correlated with other indicators of endothelial 
cell activation such as increased vWf, as well as with the levels of other endothelial cell proteins 
such as thrombomodulin and adhesion molecules including soluble intercellular adhesion 
molecule 1 (sICAM-1) and soluble vascular cell adhesion molecule 1 (sVCAM-1).  Furthermore, 
immunohistochemistry studies demonstrated the presence of elevated expression of endothelin-1 
and endothelin receptors in  pulmonary parenchyma at early stages of development of interstitial 
lung disease and fibrosing alveolitis of SSc [51], suggesting that ET-1 measurements may not 
only reflect crucial alterations in endothelial cell function involved in the pathogenesis of PAH 
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but may also be indicators of the profibrotic activity responsible for the exaggerated production 
of connective tissue macromolecules characteristic of the disease.   
Adhesion molecules involved in cell-cell interactions and cell-extracellular matrix 
interactions are also important in the pathogenesis of the earlier stages of vascular alterations in 
SSc and have been suggested as potential biomarkers for SSc vasculopathy.  Increased 
expression of endothelial leukocyte adhesion molecule 1 (ELAM-1), intercellular adhesion 
molecule 1 (ICAM-1), vascular adhesion molecule 1 (VCAM-1), e-selectin and p-selectin has 
been found in affected skin from SSc patients with higher levels present in samples from the 
diffuse form of the disease, indicating that these proteins may participate in the early stages of 
tissue fibrosis as well.  Elevated serum levels of these adhesion molecules have been found in 
SSc patients compared to normal individuals [52-54] and other studies demonstrated that these 
levels correlated with increased severity and extent of visceral organ involvement in the disease 
[55].   
Numerous recent studies have also shown that in addition to functional abnormalities in 
endothelial cells in SSc, there might be abnormalities in angiogenesis and endothelial repair.  
The rarefaction of small capillaries with a reduction in capillary density in affected SSc tissues is 
consistent with abnormal and disordered angiogenesis.  Therefore, markers that may reflect the 
angiogenesis process have been suggested as important in the evaluation of vascular alterations 
in SSc [56].  One of the key mediators of angiogenesis, VEGF, has been studied extensively as a 
potential biomarker for the vascular abnormalities in SSc [41,42,56-58]. Indeed, high VEGF 
levels have been found in patients with early SSc and these levels correlated with the presence of 
pulmonary fibrosis and abnormalities in pulmonary function including reductions in vital 
capacity and DLCO.  High levels of VEGF were also found to correlate with shorter disease 
duration as well as with aggressive and rapidly progressive diffuse cutaneous SSc, although other 
studies failed to show such a correlation [59].  
 
Biomarkers of Pulmonary Hypertension 
Pulmonary artery hypertension (PAH) has recently emerged as one of the most important 
and serious clinical problems in patients with SSc [60,61].  Although PAH is not the most 
common pulmonary involvement in SSc patients, it frequently leads to severe respiratory 
disability and often to a fatal outcome with a high mortality.  In most instances the clinical 
course of untreated PAH is one of rapid progression leading to respiratory failure or to death 
within two to three years after it becomes clinically detectable. Currently, owing to the 
remarkable reduction in mortality from SSc renal crisis, it is apparent that PAH has become one 
of the leading causes of mortality in this disease [60,62].  PAH in patients with SSc can occur as 
a sequelae to interstitial lung disease, although often it develops as a late manifestation in 
patients with the limited cutaneous form of SSc in the absence of pulmonary fibrosis.  There are 
no currently validated laboratory tests or serologic markers that can provide a specific diagnostic 
for PAH.  However, given the important role that ET-1 plays in the pathogenesis of PAH and the 
remarkable clinical effects and survival improvement resulting from the therapeutic use of 
endothelin-1 receptor blockade, measurements of circulating ET-1 levels were examined as 
possible biomarkers for SSc-related PAH [50,51] and a more recent study showed that ET-1 
plasma levels were significantly higher in SSc patients with PAH and with positive 
anticentromere antibodies.  Furthermore, there was a positive linear correlation between these 
levels and systolic pulmonary artery pressure [63].  Thus, it was suggested that ET-1 plasma 
levels may be a biomarker for detection and monitoring of PAH in SSc.  Recent interest has also 
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been focused on the measurement of plasma levels of NT-pro-BNP.  Although the plasma levels 
of this peptide reflect myocardial responses to various stimuli such as mechanical stretch or 
hypoxia and are not specific for PAH, recent studies showed that plasma NT-pro-BNP 
determinations may predict prospectively the development of clinical PAH, may also be 
indicative of survival, and may represent an accurate surrogate marker to follow the response and 
evaluate the effects of therapeutic agents for SSc related PAH [64-68].  
 
Biomarkers of Pulmonary Fibrosis 
In recent years, interstitial lung disease associated with SSc has become the leading cause 
of morbidity and mortality in the disease [62].  Thus, the search for biomarkers that may predict 
the development of pulmonary fibrosis and/or correlate with the clinical course and clinical 
response to potential therapeutic agents has become an important goal and numerous studies 
have been performed to identify such biomarkers [70,71].  Substantial interest has been placed 
on proteins that are synthesized, produced and secreted by type II alveolar epithelial cells.  Some 
of these proteins appear to predict the progression of interstitial lung involvement and may also 
represent early markers indicative of the development of this complication.  Three proteins that 
appear to be specific for pulmonary involvement are the Krebs von den Lungen 6 antigen (KL-6) 
and pulmonary surfactants A and D (PS-A and –D).  Several studies have demonstrated that 
serum levels of KL-6 as measured by ELISA are substantially higher in SSc patients than in 
normal individuals [72-74].  Furthermore, these levels were substantially higher in patients with 
pulmonary fibrosis compared to patients without lung involvement.  An important study 
performed a longitudinal evaluation of KL-6 levels in sera of a large cohort of SSc patients. The 
results showed a marked elevation of KL-6 levels, which occurred in close temporal association 
with the clinical diagnosis of pulmonary fibrosis, particularly in patients with positive anti-
topoisomerase-1 antibodies [75].  Measurements of PS-A and –D were also performed in a 
cohort of Japanese patients with SSc and it was found that both surfactant-related proteins were 
significantly elevated in patients with a diagnosis of interstitial lung disease [76].  The same 
study showed that the sensitivity for the diagnosis and identification of pulmonary fibrosis was 
higher for the PS-D isoform than for the PS-A isoform.  In contrast, the specificity for PS-A was 
higher (100% compared to 83%) than the specificity for PS-D. A correlation with functional 
abnormalities was also established and an important study showed that the levels of PS-D 
displayed a negative correlation with vital capacity and diffusion capacity for carbon monoxide 
[71].  Comparative studies of KL-6 and PS-D demonstrated that there was a positive correlation 
between the levels of both proteins and there was similarity as well in their sensitivity and 
specificity for the diagnosis of interstitial lung disease [77].  A recent study of the cohort 
included in the Scleroderma Lung Study examined the baseline levels of PS-D and KL-6 in 
patients with or without alveolitis as defined by high resolution computerized tomography and 
bronchioalveolar lavage and found that SSc patients overall had higher values for both proteins 
than normal individuals.  Furthermore, significant differences were found in these levels in SSc 
patients with alveolitis compared to those without alveolitis [78].   
Another potential marker of pulmonary involvement is the pulmonary and activation 
regulated chemokine (PARC).  This chemokine is also known as CCL-18 and it has been found 
to be elevated in patients with SSc was associated with the development of pulmonary fibrosis as 
well as with reductions in vital capacity and diffusion capacity and correlated closely with the 
activity of inflammatory changes in the lungs [79].  Furthermore, PARC levels in 
bronchioalveolar lavage from SSc patients with active alveolitis correlated with the presence of 
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an inflammatory process in the lungs as well as with the number and type of inflammatory cells 
[80].   
A recently identified glycoprotein belonging to the chitinase family, YKL-40, has also 
been suggested as a potential marker for pulmonary involvement in SSc [81,82].  Recent studies 
suggested that levels of YKL-40 may correlate with tissue remodeling and, therefore, may be of 
value in the assessment of the pulmonary fibrotic process associated with SSc.  Although earlier 
results were encouraging,  elevated levels of the protein have been found in a variety of clinical 
conditions including liver fibrosis and numerous malignancies, therefore, the utility of YKL-40 
measurements for SSc associated pulmonary fibrosis needs further evaluation. 
 
Biomarkers of cellular immune system and cytokine alterations 
 The presence of mononuclear cell infiltrates in affected skin and visceral organs from 
SSc patients has long been recognized.  Early in the presentation of SSc, biopsies from affected 
skin show prominent infiltration with activated macrophages and T- and B-cell lymphocytes 
[83].  Further expansion of T-cells within the affected tissues appears to be oligoclonal as shown 
in studies of T-cell receptor transcripts in SSc skin [84].  The expanded T-cell populations in 
affected SSc tissues release numerous cytokines, chemokines and growth factors which initiate 
and/or perpetuate the fibrotic process as well as the endothelial and vascular alterations.  
Important effects of these released soluble products include modulation of fibroblast 
proliferation and induction of expression of a myofibroblast phenotype with the acquisition of 
motile cell features, expression of α smooth muscle actin, and marked increase in their levels of 
collagen production.  These cytokines and growth factors also exert potent effects on vascular 
wall cells which result in the development of the typical fibroproliferative/occlusive 
vasculopathy including stimulation of proliferation of smooth muscle cells in the media and 
modification of numerous endothelial cell functions. 
Given the crucial role that inflammatory cells and the chronic inflammatory process play 
in the pathogenesis of various aspects of SSc, extensive efforts have been devoted to identify 
biomarkers that may reflect the cytokine, chemokine, and growth factor alterations in the disease. 
The soluble receptor for interleukin 2 (srIL-2) was one of the earliest identified biomarkers 
reflecting inflammatory and immunologic activation in SSc.  Several studies demonstrated a 
close correlation of serum levels of srIL-2 with clinical and disease activity in patients with SSc 
[85-87].  In one of these studies the levels of srIL-2 correlated inversely with the duration of SSc, 
being more elevated in patients with recent onset and rapidly progressive forms of the disorder 
[85].  The values also correlated with the severity and extent of skin sclerosis, as assessed by the 
modified Rodnan skin score.  The serum levels of the soluble receptor for TNF-α (srTNF-α) have 
also been proposed as indicators of activity of the immunologic process in SSc and significant 
correlations with the severity of SSc and the presence of pulmonary involvement have been 
described [88,89].  However, subsequent studies have not confirmed that the serum levels of 
srTNF-α are useful indicators of the severity or of the rate of progression of the disease and 
additional studies are required to further evaluate the validity of srTNF-α serum levels as 
indicators of the ongoing inflammatory and immune dysfunction in SSc.   
A recent study measured the levels of the chemokine CCL-2 in a large cohort of SSc 
patients and found higher levels in both diffuse and limited cutaneous SSc clinical subsets, 
although marked CCL-2 elevations were associated with anti-topoisomerase or anti-RNA 
polymerase I/III antibodies and with greater frequency of pulmonary and cardiac involvement 
[90].  Another study examined CCL-2 and CXCL-10 longitudinally and found that CXCL-10 
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levels were substantially elevated in newly diagnosed SSc and the highest values were associated 
with more severe clinical manifestations including pulmonary and kidney involvement [91].  The 
longitudinal study demonstrated a reduction in CXCL-10 with stable levels of CCL-2, suggesting 
a temporal switch from a Th1 to a Th2 stage [91]. The value of these two chemokines as 
biomarkers for SSc, however, must be tempered by recent studies which showed elevated levels 
in other disorders including autoimmune thyroiditis, hepatitis C infection and psoriatic arthritis. 
Numerous other cytokines, chemokines and regulatory proteins that have been considered to be 
important participants in the immune activation in SSc have been suggested as potential 
biomarkers including CD-40, CCL-2, IL-15, IL-23, BAFF, FAS, and others [92-97].  However, 
further studies to validate their sensitivity and specificity and to confirm their potential 
usefulness as biomarkers of this process will be required.   
 
Specific Biomarkers for Fibrosis 
Tissue fibrosis is the hallmark of SSc and is responsible for most of its clinical 
manifestations. The extent and severity of tissue fibrosis correlate with prognosis and mortality 
in SSc. Thus, there is an unmet need for reliable and accurate biomarkers that reflect the fibrotic 
process in SSc.  Since the discovery of the potent profibrotic and immunomodulatory activities 
of TGF-β, this pleotropic growth factor has been considered a crucial participant in the 
pathogenesis of the fibrotic process in SSc and other fibroproliferative diseases [98-100].  One of 
the most important effects of TGF-β is the stimulation of synthesis and production of numerous 
extracellular matrix (ECM) molecules involved in tissue fibrosis.  TGF-β also decreases the 
synthesis of collagen-degrading metalloproteinases and stimulates the production of protease 
inhibitors such as tissue inhibitors of metalloproteinases-1 (TIMP-1).  TGF-β also induces tissue 
resident fibroblasts to change their differentiated phenotype and become myofibroblasts, 
activated cells capable of producing elevated levels of ECM macromolecules and expressing α-
smooth muscle actin.  In addition to TGF-β, numerous studies have shown that connective tissue 
growth factor (CTGF) also plays a crucial role in tissue fibrosis owing to its potent profibrotic 
effects [101]. TGF-β stimulates CTGF synthesis in fibroblasts, vascular smooth muscle cells and 
endothelial cells.  CTGF also appears to have an autocrine function stimulating its own 
production and, thus, maintaining a continuous or prolonged cycle of excessive scarring and 
fibrosis.     
The crucial role of TGF-β and CTGF in tissue fibrosis suggests that measurements of 
their serum levels may reflect the activity of the fibrotic process.  However, a recent study 
measuring TGF-β levels in sera from patients with diffuse SSc in comparison with sera from 
patients with limited SSc and normal controls failed to show a correlation with the mRSS, 
although the values were lower in patients with diffuse SSc than in patients with limited SSc, and 
were even lower than in normal individuals [102].  Few studies have performed measurements of 
CTGF although it appears that a circulating peptide containing the N-terminal region of CTGF 
may be of value as a biomarker of tissue fibrosis [103].  Thus, extensive studies will be required 
to validate whether measurements of serum levels of these growth factors may be useful 
biomarkers for the process of fibrosis in the disease. 
 The increased expression of the genes encoding interstitial collagens types I and III and  
the marked elevation of the production of the corresponding proteins in SSc led to numerous 
studies investigating circulating or urinary levels of collagen molecules or collagen fragments as 
biomarkers that may reflect the activity of the ongoing fibrotic process [104-109].  The serum 
levels of the telopeptide corresponding to the crosslinked carboxy-terminal end of type I collagen 
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as well as the amino-terminal propeptide of type I procollagen have been given substantial 
attention since they reflect the degradation and synthesis of type I collagen, respectively.  In one 
study the levels of the crosslinked carboxy-terminal telopeptide were elevated in greater than 
80% of patients with SSc and displayed a positive correlation with the extent of skin 
involvement [104].  The measurements of the type I procollagen peptide, however, did not 
discriminate between normal individuals and patients with SSc in this study.  A more recent 
study [105] showed that approximately 50% of SSc patients had increased serum levels of the 
carboxy-terminal telopeptide of type I collagen and that these levels correlated with the mRSS 
and were higher in patients with diffuse cutaneous involvement.  The measurements of the 
amino-terminal type III collagen propeptides appear to be more reflective of the activity of the 
fibrotic process and  substantially elevated levels are found in patients with SSc compared to 
controls and in patients with diffuse cutaneous SSc and increasing clinical activity [106,107].  
Elevated levels of type III procollagen peptides also correlated with pulmonary involvement, 
reduction in vital capacity and diffusion capacity, as well as with the extent of cutaneous 
involvement [107,108], and were an independent predictor of a poor prognosis and an 
unfavorable survival [109].  Although the measurements of metabolites derived from the 
biosynthesis and degradation of types I and III collagens are very likely a reflection of the 
fibrotic process, owing to the fact that most of the type I collagen in the body is present in bone, 
metabolites derived from this molecule would reflect, to a large extent, the remodeling and 
degradation of type I collagen in the skeletal system.  In contrast, the levels of type III collagen 
metabolites may be more reflective of a fibrotic process, particularly at the earlier stages of the 
disease since it has been generally accepted that type III collagen synthesis is disproportionately 
increased at the initiation of tissue fibrosis.   
Another protein that has been suggested as a potential biomarker to reflect the fibrotic 
process in SSc is the cartilage oligomeric matrix protein (COMP), which is also an important 
fibroblast product.  Indeed, some studies have measured serum levels of COMP and described 
significant correlations with the extent of skin involvement and with the severity of SSc [110].  
Increased expression of COMP was also demonstrated in skin samples from SSc patients as well 
as in fibroblasts cultured from these samples [111,112].   However, more extensive studies 
would be required to confirm the validity of COMP as a marker of tissue fibrosis in SSc.   
 
Analysis of Gene Expression Employing Microarrays 
The recent development of high throughput gene expression profiling technologies such 
as cDNA microarrays, combined with advanced computational approaches, have provided basic 
and clinical investigators with the ability to identify and characterize high-resolution expression 
profiles of numerous disease states and to dissect molecular networks that underlie specific 
disease phenotypes.  Within a few years following their introduction, microarrays are now 
routinely used in almost every line of biomedical research with the most impressive examples of 
the successful utilization of this technology in cancer research.  In the field of SSc research, the 
application of microarray technology holds the promise that it may allow the identification of 
molecular signatures specific for SSc, which could provide clues to the elucidation of the 
pathogenetic mechanisms involved or responsible for the disease as well as  valuable molecular 
signatures that can be used as biomarkers of utility as diagnostic or prognostic tools and as 
markers of the effectiveness of disease modifying therapies.  Indeed, recent microarray studies of 
intact skin, peripheral blood mononuclear cells or cultured dermal fibroblasts disclosed distinct 
patterns of gene expression capable of distinguishing patients with limited SSc from those with 
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diffuse SSc and allowing the identification of separate subsets within these two groups that 
correlate with various clinical parameters and internal organ involvement [113-118].  Microarray 
studies have also been employed to identify specific patterns of gene expression in SSc 
associated pulmonary fibrosis [119] and pulmonary hypertension [120] and have identified a 
subset of SSc patients who display a TGF-β signature in their skin [121].  Thus, global gene 
expression studies promise to provide molecular signatures which will be useful as molecular 
biomarkers for the diagnosis of SSc, identification of its clinical subsets, evaluation of 
effectiveness of disease-modifying therapies, and to stratify patients who may respond and 
benefit from specific therapies, as shown recently for imatinib mesylate [121,122]. 
 
Use of Proteomics to Identify Biomarkers 
The field of proteomics is defined as the study of the entire complement of proteins 
(proteome) present or produced by a cell or organism employing large scale separation and 
identification.  Proteomic studies related to human diseases attempt to assess and identify 
qualitative and quantitative protein differences between healthy and diseased cells.  The 
remarkable technical advances and instrumentation development achieved in the last decade 
have been successfully applied to numerous biological fields including the discovery of 
biomarkers.  However, proteomics studies in SSc have been very limited and the few studies 
available have mainly focused on the understanding of pathophysiologic events rather than in the 
identification of disease biomarkers [123,124]. 
 
Future Perspective 
The diagnosis of SSc at an early stage prior to the occurrence of obvious cutaneous 
fibrosis is a challenging task. The assessment and unequivocal assignment of SSc clinical subset 
(i.e.: diffuse cutaneous versus limited cutaneous) and the evaluation of clinical effectiveness of 
therapeutic interventions is of great relevance to patient management. The ability to accurately 
separate SSc patients with rapid progression from those with slow progression and to estimate 
the prognosis of the disease would also be of remarkable clinical and therapeutic value.  
Although there has been substantial effort devoted to the development and identification of 
useful biomarkers for SSc we are still very far from reaching the full potential of biomarker 
research for SSc. The application of novel genomic, global gene expression, and proteomic 
approaches opens up new and promising opportunities to approach this lofty goal. 
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Executive Summary  
• Despite extensive studies to develop outcome measures for SSc, fully validated biomarkers 
that allow early diagnosis and assessment of disease activity or that carry a predictive 
prognostic value are not available. 
Autoantibodies as Systemic Sclerosis Diagnostic Biomarkers 
• Numerous circulating autoantibodies highly specific for SSc, e.g., anti-Scl-70 and anti-
centromere antibodies are used as diagnostic biomarkers to support or confirm the 
clinical diagnosis of SSc. 
Biomarkers for Clinical Disease Subset Classification 
• Some autoantibodies are biomarkers of the clinical disease subset, namely anticentromere 
antibodies for limited SSc subset, and Scl-70, anti RNA polymerase I and III, and anti-
fibrillarin antibodies for the diffuse form of SSc. 
Biomarkers of Endothelial Cell Dysfunction   
• Numerous molecules involved in various aspects of the pathogenesis of endothelial 
dysfunction (e.g., von Willebrand factor, adhesion molecules, vascular endothelial 
growth factor) are potential biomarkers for endothelial perturbations in SSc.   
Biomarkers of Pulmonary Hypertension 
• Endothelin-1 and N-terminal pro-brain natriuretic peptide plasma levels are biomarkers 
for detection and monitoring of pulmonary artery hypertension (PAH) and may be 
surrogate markers to evaluate the effects of therapeutic agents for SSc related PAH. 
Biomarkers of Pulmonary Fibrosis 
• Serum levels of KL-6, pulmonary surfactants A and D, and PARC are indicators of the 
development of pulmonary fibrosis in SSc. 
Biomarkers of cellular immune system and cytokine alterations 
• The levels of numerous cytokines and chemokines that reflect the participation of 
immune and inflammatory processes have been suggested as potential biomarkers. 
Specific Biomarkers for Fibrosis 
• Circulating or urinary levels of molecules or fragments of interstitial type I and III 
collagens are potential biomarkers for the activity of the ongoing fibrotic process.   
• Elevated levels of type III procollagen peptides correlate with pulmonary involvement 
and predict a poor prognosis and an unfavorable survival. 
Analysis of Gene Expression Employing Microarrays and Use of Proteomics to Identify 
Biomarkers 
• The application of novel genomic, global gene expression, and proteomic approaches 
opens up new and promising opportunities for the development of useful SSc biomarkers 
and has already allowed the identification of patient subsets with specific signatures that 
may indicate different pathophysiological events or differential therapeutic responses. 
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Table 1.   Potential biomarkers for SSc diagnosis, clinical subset classification, and 
process/organ involvement. 
Biomarker Class/Function Clinical Association Response to Treatment 
Diagnostic and  Clinical Subset Classification 
anti-Scl-70 Anti-DNA topoisomerase I antibody Diffuse SSc, Pulmonary fibrosis No 
anti-centromere Anti-Kinetochore protein antibody Limited SSc, Pulmonary hypertension No 
anti-RNA polymerase I 
anti-RNA polymerase III Antibodies to RNA polymerases 
Diffuse SSc,  
renal involvement No 
anti-fibrillarin Antibody to 34 kDa nucleolar protein 
component of U3-RNP Diffuse SSc No 
anti-PM-Scl Antibody to complex of 110-20 kDA 
nucleolar and nuclear proteins Polymyositis/SSc overlap No 
Anti-Th/To Antibody to RNAse P 
ribonucleoprotein complexes Limited SSc No 
Vascular 
von Willebrand factor (vWf) Hemostasis 
Endothelial cell 
dysfunction, SSc severity, 
ILD extent 
Unknown 
Adhesion molecules Cell-cell interactions Endothelial cell dysfunction Unknown 
Vascular endothelial growth 
factor (VEGF) Growth factor Endothelial cell dysfunction Unknown 
Fibrotic 
Type III procollagen peptides Fibroblast and endothelial cell 
extracellular matrix protein 
Pulmonary involvement, 
poor prognosis/survival Yes 
Transforming growth factor- β  
(TGF- β )  Growth factor Fibrosis Unknown 
Connective tissue growth 
factor (CTGF) Growth factor Fibrosis Unknown 
Cartilage oligomeric matrix 
protein (COMP) 
Cartilage and fibroblast extracellular 
matrix protein Fibrosis Unknown 
Immunologic (Cytokines and Chemokines) 
soluble receptor for interleukin 
2 (srIL-2) 




soluble receptor for tissue 
necrosis factor- α  (srTNF- α ) 





Endothelin-1 (ET-1) Vasoconstrictor Endothelial cell product 
Pulmonary artery 
hypertension Yes 
N-terminal pro-brain natriuretic 
peptide (NT-pro-BNP) 





Krebs von den Lungen 6 
antigen (KL-6) 
Mucinous glycoprotein from type II 
pneumocytes Pulmonary fibrosis Yes 
Pulmonary surfactant A  Product of type II pneumocytes Pulmonary fibrosis (sensitive) Yes 
Pulmonary surfactant D  Product of type II pneumocytes Pulmonary fibrosis (specific) Unknown 
Pulmonary and activation 
regulated chemokine (PARC) Chemokine Pulmonary fibrosis Unknown 
YKL-40 (human cartilage 
glycoprotein-39 (HC gp-39)) Tissue remodeling Pulmonary fibrosis Unknown 
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Figure 1. General overview of the pathogenesis of SSc. The illustrations on the bottom row 
show examples of, from left to right, the fibrotic process (biopsy of skin), microvascular 
alterations in pulmonary arterioles, autoantibodies detected by immunofluorescence, and 
mononuclear inflammatory cell infiltrates in affected skin.  Adapted from Reference 3. 
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Figure 2.  Postulated sequence of events in the pathogenesis of SSc.  Sequence of pathogenic 
processes leading to tissue fibrosis and autoantibody production.  The process is initiated by 
microvascular injury which induces chronic inflammation with participation of macrophages and 
T lymphocytes, as well as B lymphocyte activation leading to autoantibody production.  The 
secreted products from the inflammatory cells result in fibroblast activation and phenotypic 
conversion into myofibroblasts, key events in the development of fibrosis.   
 
